
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)

Strata Critical Medical, Inc.

(Name of Issuer)

Warrants to purchase Class A Common Stock, par value \$0.0001 per share

(Title of Class of Securities)

092667104

(CUSIP Number)

**Velibor Krstic
Via Baraggie 23,
Ascona, V8, 6612
0041774839182**

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

04/08/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP 092667104
Number(s):

1	Name of reporting person Krstic Velibor
2	Check the appropriate box if a member of a Group (See Instructions) <input type="checkbox"/> (a) <input type="checkbox"/> (b)
3	SEC use only

4	Source of funds (See Instructions) PF, PF	
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) <input type="checkbox"/>	
6	Citizenship or place of organization SWITZERLAND	
Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 1,139,393.00
	8	Shared Voting Power 0.00
	9	Sole Dispositive Power 1,139,393.00
	10	Shared Dispositive Power 0.00
11	Aggregate amount beneficially owned by each reporting person 1,139,393.00	
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) <input type="checkbox"/>	
13	Percent of class represented by amount in Row (11) 12.4 %	
14	Type of Reporting Person (See Instructions) IN, IN	

SCHEDULE 13D

Item 1. Security and Issuer

(a) **Title of Class of Securities:**

Warrants to purchase Class A Common Stock, par value \$0.0001 per share

(b) **Name of Issuer:**

Strata Critical Medical, Inc.

(c) **Address of Issuer's Principal Executive Offices:**

31 HUDSON YARDS, 31 HUDSON YARDS, NEW YORK, NEW YORK , 10001.

Item 2. Identity and Background

(a) Velibor Krstic

(b) Via Baraggie 23, 6612 Ascona, SWITZERLAND

(c) Private Investor

(d) NONE

(e) NONE

(f) SWITZERLAND

Item 3. Source and Amount of Funds or Other Consideration

The total amount of funds used by the Reporting Person to purchase the 1,139,393 Warrants reported herein was approximately 19,380 dollars. All such funds were provided from the Reporting Person personal funds.

Item 4. Purpose of Transaction

The Reporting Person acquired the Warrants and the shares of Common Stock for investment purposes. The Reporting Person believes that the current market price of the Warrants (SRTAW) is significantly undervalued relative to the fundamentals of the Issuer, particularly considering the Adjusted EBITDA of 14.1 million dollars and the successful integration of Keystone Perfusion. The Reporting Person has been a shareholder of the Issuer since July 10, 2024, holding 26,425 shares of Common Stock. This long term ownership demonstrates a consistent commitment to the Issuer and an alignment of interests with all stakeholders. The Reporting Person intends to actively monitor the decisions of the Board of Directors and management leading up to the Warrant expiration date of May 7, 2026. The Reporting Person may engage in discussions with the Issuer, the Sponsor (KSL Capital Partners), and other relevant shareholders to discuss options aimed at maximizing the value of the investment, including, but not limited to, the implementation of a voluntary Exchange Offer or an amendment to the Warrant Agreement. Except as set forth above, the Reporting Person has no current plans or proposals that relate to or would result in any of the actions listed in paragraphs (a) through (j) of Item 4 of Schedule 13D.

Item 5. Interest in Securities of the Issuer

- (a) As of April 8, 2026, the Reporting Person beneficially owns 1,139,393 Warrants, which represent approximately 12.4 percent of the 9,166,644 public warrants outstanding. This percentage is based on the number of Public Warrants reported by the Issuer in its most recent Annual Report on Form 10-K. Additionally, for transparency, the Reporting Person owns 26,425 shares of Common Stock (SRTA) acquired on July 10, 2024, representing approximately 0.03 percent of the 86,989,143 shares of Common Stock outstanding as of February 24, 2026.
- (b) The Reporting Person has the sole power to vote or to direct the vote, and the sole power to dispose or to direct the disposition of, all 1,139,393 Warrants and all 26,425 shares of Common Stock reported in Item 5(a).
- (c) On April 8, 2026, the Reporting Person purchased 374,958 Warrants in open market transactions at a weighted average price of approximately 0.011 dollars per Warrant. In the aggregate, during the past 60 days, the Reporting Person has acquired 1,139,393 Warrants for a total purchase price of approximately 19,380 dollars. The most recent transaction, which resulted in the Reporting Person becoming the beneficial owner of more than 12 percent of the class, occurred on April 8, 2026.
- (d) No other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Warrants or the shares of Common Stock reported herein.
- (e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

To the best knowledge of the Reporting Person, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the person named in Item 2 and between such person and any person with respect to any securities of the Issuer, including but not limited to, transfer or voting of any of the securities, finders fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.

Item 7. Material to be Filed as Exhibits.

NONE

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Krstic Velibor

Signature: /s/ VELIBOR KRSTIC
Name/Title: VELIBOR KRSTIC, INDIVIDUAL INVESTOR
Date: 04/08/2026